Skip to main content

Table 3 Survival rates

From: Combination therapy with Olaratumab/doxorubicin in advanced or metastatic soft tissue sarcoma -a single-Centre experience

 

all patients

patients receiving systemic therapy only

patients receiving surgical intervention

 

n = 32

n = 23

n = 9

PFS median (range)

3.1 (0.6–16.2)

2.8 (0.6–16.2)

4.7 (2.1–11.9)

OS median (range)

4.6 (1.6–17.5)

3.9 (1.6–17.5)

7.4 (3.3–16.6)

  1. PFS progression free survival; OS overall survival